Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.53 |
| ▸ | LTB4R | Q15722 | 4/20 | 0.48 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040469 | 0.92 | LTA4H (0.51) | LTB4RLTB4R2LTA4HKDM1ASIGMAR1 | |
| SCHEMBL3039367 | 0.88 | LTA4H (0.59) | FFAR1LTA4HSIGMAR1FFAR2 | |
| SCHEMBL30567407 | 0.84 | LTA4H (0.47) | FFAR1LTA4HSIGMAR1S1PR5 | |
| SCHEMBL3042583 | 0.84 | LTA4H (0.61) | FFAR1LTA4HSIGMAR1S1PR5 | |
| SCHEMBL3334872 | 0.82 | FFAR1 (0.76) | FFAR1LTB4RLTB4R2LTA4H | |
| SCHEMBL3040767 | 0.80 | LTA4H (0.55) | FFAR1LTA4H | |
| SCHEMBL3039090 | 0.80 | LTA4H (0.65) | LTA4HKDM1ASIGMAR1 | |
| SCHEMBL3042625 | 0.76 | LTA4H (0.57) | LTA4H | |
| SCHEMBL3713589 | 0.74 | S1PR5 (0.76) | SIGMAR1S1PR5 | |
| SCHEMBL9826020 | 0.74 | FFAR1 (0.67) | FFAR1LTB4RLTB4R2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976828-B1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2016-12-21 | — | — | EP | claimed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | claimed |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | CELLTAXIS LLC (US) | 2025-09-25 | — | — | US | disclosed |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELLTAXIS, LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS LLC (US) | 2023-08-10 | — | — | US | disclosed |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | ALKAHEST, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | Celltaxsis, LLC (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | ALKAHEST, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2020-10-01 | — | — | US | disclosed |
| US-9315509-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | DOMAIN PARTNERS VIII, L.P. | 2015-03-19 | — | — | US | disclosed |
| US-8569303-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. | 2013-05-16 | — | — | US | disclosed |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | ESTRELLITA PHARMACEUTICALS, LLC | 2010-08-19 | — | — | US | disclosed |
| US-7737145-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | ESTRELLITA PHARMACEUTICALS, LLC (US) | 2010-06-15 | — | — | US | disclosed |
| EP-1976828-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Schering Aktiengesellschaft (DE) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007079078-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-07-12 | — | — | WO | disclosed |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123243-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-11344542-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 845/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-12173009-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-11426399-B2 | Treatment of aging-associated disease with modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 845/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20150080382-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20220226304-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 845/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20250296935-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20070155726-A1 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-11267819-B2 | Diamine derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20230250104-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20200308181-A1 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20100210630-A1 | Diamine Derivatives as Inhibitors of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 233/4885LTB4R 2/4885LTB4R2 4/4885 |
| US-20200368220-A1 | Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase | LTA4H, LTB4R, LTC4S | FFAR1 845/4885LTB4R 2/4885LTB4R2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.